secwatch.observer — SEC 8-K summary
======================================

Issuer:     Trevi Therapeutics, Inc. (TRVI)
CIK:        0001563880
Form:       8-K
Filed at:   2022-06-29T23:59:59+00:00
Accession:  0001564590-22-024605
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Trevi Therapeutics reports positive Phase 2b/3 PRISM trial for Haduvio in prurigo nodularis
--------------------------------------------------------------------------------

- Primary endpoint met: 25% of Haduvio subjects achieved 4-point WI-NRS reduction vs 14% placebo (p=0.0157).
- Significant improvement in ItchyQoL (p=0.0002) and Prurigo Activity Scale (p=0.006) at week 14.
- Safety profile consistent with prior trials; discontinuations 36.9% Haduvio vs 19.3% placebo.
- Cash and investments expected ~$78M at June 30, 2022; plans to discuss data with FDA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563880/000156459022024605/0001564590-22-024605-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563880/000156459022024605/trvi-8k_20220629.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-024605

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer